Overview |
bsm-54571R |
ACE2 Monoclonal Antibody |
WB, IHC-P, IF(ICC), IP, IHC |
Human, Mouse, Rat, Hamster |
Specifications |
Unconjugated |
Rabbit |
Synthetic Peptide within Human ACE2 aa 200-230. |
Monoclonal |
3B5 |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
Store at -20°C for 12 months. |
Target |
59272 |
Q9BYF1 |
Cytoplasm, Secreted, Cell membrane |
ACE 2 antibody, ACE related carboxypeptidase antibody, ACE-related carboxypeptidase antibody, ACE2 antibody, ACE2_HUMAN antibody, ACEH antibody, Angiotensin converting enzyme 2 antibody, Angiotensin converting enzyme homolog antibody, Angiotensin converting enzyme like protein antibody, Angiotensin I Converting Enzyme (peptidyl dipeptidase A) 2 antibody, Angiotensin I converting enzyme 2 antibody, Angiotensin-converting enzyme homolog antibody, DKFZP434A014 antibody, EC 3.4.17 antibody, metalloprotease MPROT 15 antibody, Metalloprotease MPROT15 antibody, OTTHUMP00000022963 antibody, Processed angiotensin-converting enzyme 2 antibody |
Angiotensin converting enzyme 2 (ACE2) is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin[1-9], or the conversion of angiotensin II to angiotensin 1-7. ACE2 has direct effects on cardiac function,a and is expressed predominantly in vascular endothelial cells of the heart and the kidneys. ACE2 is not sensitive to the ACE inhibitor drugs used to treat hypertension. ACE2 receptors have been shown to be the entry point into human cells for some coronaviruses, including the SARS virus[10]. A number of studies have identified that the entry point is the same for SARS-CoV-2, the COVID-19 virus. |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |
IF(ICC) |
1:50-200 |
IP |
1-2ug |
IHC |
|